Contact
searchSearch
HMP Global
Login

Metastatic Colorectal Cancer Specialty Channel

Metastatic Colorectal Cancer
Specialty Channel
Quiz
Tucatinib Plus Trastuzumab for HER2-Posititive Metastatic Colorectal Cancer
03/18/2026
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the...
03/18/2026
Oncology
News
Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative...
03/18/2026
Oncology
FDA Approval
FDA Grants Traditional Approval to Encorafenib-Cetuximab Plus Chemotherapy for BRAF V600E-Mutant Metastatic Colorectal Cancer
02/24/2026
Gina Tomaine
On February 24, 2026, the FDA granted traditional approval to frontline encorafenib in combination with cetuximab and fluorouracil-based chemotherapy for patients with metastatic colorectal cancer harboring a BRAF V600E mutation, as detected...
On February 24, 2026, the FDA granted traditional approval to frontline encorafenib in combination with cetuximab and fluorouracil-based chemotherapy for patients with metastatic colorectal cancer harboring a BRAF V600E mutation, as detected...
On February 24, 2026, the FDA...
02/24/2026
Oncology
News
Zanzalintinib Plus Atezolizumab Significantly Improves OS in Relapsed or Refractory Metastatic Colorectal Cancer
02/06/2026
Stephanie Holland
Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab significantly improves overall survival compared with regorafenib in relapsed or refractory metastatic colorectal cancer without MSI-H or dMMR tumors.
Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab significantly improves overall survival compared with regorafenib in relapsed or refractory metastatic colorectal cancer without MSI-H or dMMR tumors.
Results from the STELLAR-303...
02/06/2026
Oncology
Quiz
Atezolizumab Plus FOLFIRINOX and Bevacizumab for dMMR/MSI-H mCRC
01/27/2026
True or False: The combination of atezolizumab with FOLFIRINOX and bevacizumab significantly prolonged progression-free survival compared with atezolizumab monotherapy among patients with treatment-naive dMMR/MSI-H metastatic colorectal...
True or False: The combination of atezolizumab with FOLFIRINOX and bevacizumab significantly prolonged progression-free survival compared with atezolizumab monotherapy among patients with treatment-naive dMMR/MSI-H metastatic colorectal...
True or False: The combination...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
Quiz
CMS4 and Anti-EGFR Benefit in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/13/2026
True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...
True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...
True or False: Consensus...
01/13/2026
Oncology
Conference Coverage
Encorafenib and Cetuximab Plus FOLFIRI Demonstrates Superior Response Rates for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.
In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.
In the BREAKWATER trial,...
01/12/2026
Oncology
News
Circulating Tumor DNA-Guided Cetuximab Rechallenge Shows Improved Outcomes for Select Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.
Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.
Data from the CAVE-2 GOIM trial...
01/12/2026
Oncology
News
CMS4 Identified as Potential Biomarker of Anti-EGFR Benefit in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
12/16/2025
Stephanie Holland
According to results from an individual patient data meta-analysis, CMS4 may serve as a predictive biomarker for improved outcomes with anti-EGFR therapy among patients with RAS and BRAF wild-type metastatic colorectal cancer.
According to results from an individual patient data meta-analysis, CMS4 may serve as a predictive biomarker for improved outcomes with anti-EGFR therapy among patients with RAS and BRAF wild-type metastatic colorectal cancer.
According to results from an...
12/16/2025
Oncology

News

News
Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative...
03/18/2026
Oncology
FDA Approval
FDA Grants Traditional Approval to Encorafenib-Cetuximab Plus Chemotherapy for BRAF V600E-Mutant Metastatic Colorectal Cancer
02/24/2026
Gina Tomaine
On February 24, 2026, the FDA granted traditional approval to frontline encorafenib in combination with cetuximab and fluorouracil-based chemotherapy for patients with metastatic colorectal cancer harboring a BRAF V600E mutation, as detected...
On February 24, 2026, the FDA granted traditional approval to frontline encorafenib in combination with cetuximab and fluorouracil-based chemotherapy for patients with metastatic colorectal cancer harboring a BRAF V600E mutation, as detected...
On February 24, 2026, the FDA...
02/24/2026
Oncology
News
Zanzalintinib Plus Atezolizumab Significantly Improves OS in Relapsed or Refractory Metastatic Colorectal Cancer
02/06/2026
Stephanie Holland
Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab significantly improves overall survival compared with regorafenib in relapsed or refractory metastatic colorectal cancer without MSI-H or dMMR tumors.
Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab significantly improves overall survival compared with regorafenib in relapsed or refractory metastatic colorectal cancer without MSI-H or dMMR tumors.
Results from the STELLAR-303...
02/06/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
Conference Coverage
Encorafenib and Cetuximab Plus FOLFIRI Demonstrates Superior Response Rates for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.
In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.
In the BREAKWATER trial,...
01/12/2026
Oncology
News
Circulating Tumor DNA-Guided Cetuximab Rechallenge Shows Improved Outcomes for Select Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.
Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.
Data from the CAVE-2 GOIM trial...
01/12/2026
Oncology
News
CMS4 Identified as Potential Biomarker of Anti-EGFR Benefit in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
12/16/2025
Stephanie Holland
According to results from an individual patient data meta-analysis, CMS4 may serve as a predictive biomarker for improved outcomes with anti-EGFR therapy among patients with RAS and BRAF wild-type metastatic colorectal cancer.
According to results from an individual patient data meta-analysis, CMS4 may serve as a predictive biomarker for improved outcomes with anti-EGFR therapy among patients with RAS and BRAF wild-type metastatic colorectal cancer.
According to results from an...
12/16/2025
Oncology
News
HER2 Alterations Signal Poorer Outcomes in Untreated RAS/BRAF Wild-Type Metastatic Colorectal Cancer
12/10/2025
Janelle Bradley
Among patients with RAS/BRAF wild-type metastatic colorectal cancer, those who harbor HER2 alterations experience significantly worse survival but show no differential benefit from first-line anti-EGFR or bevacizumab therapy, according to an...
Among patients with RAS/BRAF wild-type metastatic colorectal cancer, those who harbor HER2 alterations experience significantly worse survival but show no differential benefit from first-line anti-EGFR or bevacizumab therapy, according to an...
Among patients with RAS/BRAF...
12/10/2025
Oncology
News
Plasma Tie2 Predicts Bevacizumab Response in Patients With Metastatic Colorectal Cancer
12/03/2025
Stephanie Holland
New long-term data from the phase 2 TRAVASTIN study reinforce plasma Tie2 as a meaningful vascular response biomarker for bevacizumab among patients with metastatic colorectal cancer (mCRC).
New long-term data from the phase 2 TRAVASTIN study reinforce plasma Tie2 as a meaningful vascular response biomarker for bevacizumab among patients with metastatic colorectal cancer (mCRC).
New long-term data from the...
12/03/2025
Oncology

Interactive Features

Quiz
Tucatinib Plus Trastuzumab for HER2-Posititive Metastatic Colorectal Cancer
03/18/2026
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the...
03/18/2026
Oncology
Quiz
Atezolizumab Plus FOLFIRINOX and Bevacizumab for dMMR/MSI-H mCRC
01/27/2026
True or False: The combination of atezolizumab with FOLFIRINOX and bevacizumab significantly prolonged progression-free survival compared with atezolizumab monotherapy among patients with treatment-naive dMMR/MSI-H metastatic colorectal...
True or False: The combination of atezolizumab with FOLFIRINOX and bevacizumab significantly prolonged progression-free survival compared with atezolizumab monotherapy among patients with treatment-naive dMMR/MSI-H metastatic colorectal...
True or False: The combination...
01/27/2026
Oncology
Quiz
CMS4 and Anti-EGFR Benefit in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/13/2026
True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...
True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...
True or False: Consensus...
01/13/2026
Oncology
Quiz
Oxaliplatin-Based Chemotherapy and Targeted Agents for Metastatic Colorectal Cancer
11/24/2025
Which of the following factors was identified as prognostic for OS and PFS in patients with metastatic colorectal cancer receiving oxaliplatin-based chemotherapy plus molecular targeted agents?
Which of the following factors was identified as prognostic for OS and PFS in patients with metastatic colorectal cancer receiving oxaliplatin-based chemotherapy plus molecular targeted agents?
Which of the following factors...
11/24/2025
Oncology
Quiz
Adding Bevacizumab to Trifluridine and Tipiracil for Previously Treated Patients With Metastatic Colorectal Cancer
09/30/2025
Based on post hoc analysis results from the phase 3 SUNLIGHT trial, did the addition of bevacizumab to trifluridine and tipiracil improve tumor response among previously treated patients with metastatic colorectal cancer? Take our quiz to...
Based on post hoc analysis results from the phase 3 SUNLIGHT trial, did the addition of bevacizumab to trifluridine and tipiracil improve tumor response among previously treated patients with metastatic colorectal cancer? Take our quiz to...
Based on post hoc analysis...
09/30/2025
Oncology
Quiz
Amivantamab Rechallenge for Patients With Left-Sided Metastatic Colorectal Cancer
08/05/2025
True or False: According to updated results from the OrigAMI-1 trial, amivantamab rechallenge showed promising antitumor activity and lengthened survival end points among patients with left-sided metastatic colorectal cancer who underwent...
True or False: According to updated results from the OrigAMI-1 trial, amivantamab rechallenge showed promising antitumor activity and lengthened survival end points among patients with left-sided metastatic colorectal cancer who underwent...
True or False: According to...
08/05/2025
Oncology
Quiz
Sotorasib Plus Panitumumab and FOLFIRI for Patients With KRAS G12C-Mutated Metastatic Colorectal Cancer
07/23/2025
True or False: According to results from the phase 1b CodeBreaK 101 study, sotorasib plus panitumumab and FOLFIRI demonstrated long-term efficacy and safety among patients with KRAS G12C-mutated metastatic colorectal cancer.
True or False: According to results from the phase 1b CodeBreaK 101 study, sotorasib plus panitumumab and FOLFIRI demonstrated long-term efficacy and safety among patients with KRAS G12C-mutated metastatic colorectal cancer.
True or False: According to...
07/23/2025
Oncology

Recent News

News
Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative...
03/18/2026
Oncology
FDA Approval
FDA Grants Traditional Approval to Encorafenib-Cetuximab Plus Chemotherapy for BRAF V600E-Mutant Metastatic Colorectal Cancer
02/24/2026
Gina Tomaine
On February 24, 2026, the FDA granted traditional approval to frontline encorafenib in combination with cetuximab and fluorouracil-based chemotherapy for patients with metastatic colorectal cancer harboring a BRAF V600E mutation, as detected...
On February 24, 2026, the FDA granted traditional approval to frontline encorafenib in combination with cetuximab and fluorouracil-based chemotherapy for patients with metastatic colorectal cancer harboring a BRAF V600E mutation, as detected...
On February 24, 2026, the FDA...
02/24/2026
Oncology
News
Zanzalintinib Plus Atezolizumab Significantly Improves OS in Relapsed or Refractory Metastatic Colorectal Cancer
02/06/2026
Stephanie Holland
Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab significantly improves overall survival compared with regorafenib in relapsed or refractory metastatic colorectal cancer without MSI-H or dMMR tumors.
Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab significantly improves overall survival compared with regorafenib in relapsed or refractory metastatic colorectal cancer without MSI-H or dMMR tumors.
Results from the STELLAR-303...
02/06/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
Conference Coverage
Encorafenib and Cetuximab Plus FOLFIRI Demonstrates Superior Response Rates for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.
In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.
In the BREAKWATER trial,...
01/12/2026
Oncology
News
Circulating Tumor DNA-Guided Cetuximab Rechallenge Shows Improved Outcomes for Select Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.
Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.
Data from the CAVE-2 GOIM trial...
01/12/2026
Oncology
News
CMS4 Identified as Potential Biomarker of Anti-EGFR Benefit in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
12/16/2025
Stephanie Holland
According to results from an individual patient data meta-analysis, CMS4 may serve as a predictive biomarker for improved outcomes with anti-EGFR therapy among patients with RAS and BRAF wild-type metastatic colorectal cancer.
According to results from an individual patient data meta-analysis, CMS4 may serve as a predictive biomarker for improved outcomes with anti-EGFR therapy among patients with RAS and BRAF wild-type metastatic colorectal cancer.
According to results from an...
12/16/2025
Oncology
News
Plasma Tie2 Predicts Bevacizumab Response in Patients With Metastatic Colorectal Cancer
12/03/2025
Stephanie Holland
New long-term data from the phase 2 TRAVASTIN study reinforce plasma Tie2 as a meaningful vascular response biomarker for bevacizumab among patients with metastatic colorectal cancer (mCRC).
New long-term data from the phase 2 TRAVASTIN study reinforce plasma Tie2 as a meaningful vascular response biomarker for bevacizumab among patients with metastatic colorectal cancer (mCRC).
New long-term data from the...
12/03/2025
Oncology
News
Panitumumab Retreatment Improves Outcomes in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
11/12/2025
Stephanie Holland
Panitumumab retreatment showed improved response and disease control compared to regorafenib among patients with chemorefractory RAS and BRAF wild-type metastatic colorectal cancer who exhibited no mutations of resistance in ctDNA.
Panitumumab retreatment showed improved response and disease control compared to regorafenib among patients with chemorefractory RAS and BRAF wild-type metastatic colorectal cancer who exhibited no mutations of resistance in ctDNA.
Panitumumab retreatment showed...
11/12/2025
Oncology
FDA Approval
FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Previously Untreated Patients With Advanced Classical Hodgkin Lymphoma
03/20/2026
Emily Estrada
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG...
03/20/2026
Oncology
News
Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative...
03/18/2026
Oncology
News
Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma
03/11/2026
Stephanie Holland
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3...
03/11/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3...
03/11/2026
Oncology
News
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute
FDA Alerts
Ipsen Voluntarily Withdraws Tazemetostat Following Updated Safety Findings from the SYMPHONY-1 Trial
03/11/2026
Stephanie Holland
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data...
03/11/2026
Oncology
News
Pimicotinib Maintains Favorable Safety Profile in Tenosynovial Giant Cell Tumor
03/11/2026
Stephanie Holland
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the...
03/11/2026
Oncology
News
Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous Squamous Cell Carcinoma
03/05/2026
Stephanie Holland
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST...
03/05/2026
Oncology
FDA Approval
FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma
03/05/2026
Emily Estrada
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase...
03/05/2026
Oncology
News
Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer
03/04/2026
Emily Estrada
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study...
03/04/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use